Symbols / WINT $0.01 +11.65% Windtree Therapeutics, Inc.

Healthcare • Biotechnology • United States • OID
WINT Chart
About

Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. Its lead product candidate is istaroxime, which is in Phase 2b clinical trials for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. The company also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trials to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant for the treatment of respiratory disease, disorder, or condition in humans; Rostafuroxin, which is in Phase 2b clinical trials for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activators, which are in preclinical trials for the treatment of chronic and acute heart failure. In addition, it is developing an aPKCi inhibitor, which is in preclinical trials for the treatment of cutaneous malignancies and solid tumors. Windtree Therapeutics, Inc. has a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products; a license, development, and commercialization agreement with Lee's Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; a license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and a collaboration with Battelle Memorial Institute for the development of its aerosol delivery system. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was founded in 1992 and is headquartered in Warrington, Pennsylvania.

Fundamentals
Scroll to Statements
Sector Healthcare Industry Biotechnology Market Cap 387.65K
Enterprise Value 3.63M Income -48.83M Sales —
Book/sh -0.34 Cash/sh 0.01 Dividend Yield —
Payout 0.00% Employees 14 IPO —
P/E 0.00 Forward P/E -0.01 PEG —
P/S — P/B -0.03 P/C —
EV/EBITDA -0.24 EV/Sales — Quick Ratio 0.01
Current Ratio 0.33 Debt/Eq — LT Debt/Eq —
EPS (ttm) 323.08 EPS next Y -2.13 EPS Growth —
Revenue Growth — Earnings 2024-11-26 16:00 ROA -42.39%
ROE — ROIC — Gross Margin 0.00%
Oper. Margin 0.00% Profit Margin 0.00% Shs Outstand 33.71M
Shs Float 33.71M Short Float 6.25% Short Ratio 0.08
Short Interest — 52W High 1.86 52W Low 0.01
Beta 0.68 Avg Volume 457.64K Volume 133.64K
Target Price — Recom None Prev Close $0.01
Price $0.01 Change 11.65%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$0.01
Latest analyst target
3. DCF / Fair value
$-12.63
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.01
Low
—
High
—
Mean
—

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2024-12-04 reit HC Wainwright & Co. Neutral → Neutral $7
2024-01-03 init HC Wainwright & Co. — → Neutral $1
News
RSS: Latest WINT news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2024-10-08 FRASER CRAIG E Chief Executive Officer — 5,431 $0.91 $4,942
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
25.02
+42.65%
17.54
-19.87%
21.89
-32.15%
32.26
Research And Development
16.28
+95.13%
8.34
-24.85%
11.10
-37.60%
17.79
Selling General And Administration
8.74
-4.95%
9.20
-14.75%
10.79
-25.45%
14.47
General And Administrative Expense
8.74
-4.95%
9.20
-14.75%
10.79
-25.45%
14.47
Other Gand A
8.74
-4.95%
9.20
-14.75%
10.79
-25.45%
14.47
Total Expenses
25.02
+42.65%
17.54
-19.87%
21.89
-32.15%
32.26
Operating Income
-25.02
-42.65%
-17.54
+19.87%
-21.89
+32.15%
-32.26
Total Operating Income As Reported
-26.14
-26.91%
-20.60
+50.17%
-41.33
+46.52%
-77.28
EBITDA
-1.47
+92.69%
-20.16
+49.59%
-39.99
+48.28%
-77.32
Normalized EBITDA
-25.27
-47.79%
-17.10
+19.51%
-21.25
+34.22%
-32.30
Reconciled Depreciation
0.08
+2.44%
0.08
-84.62%
0.53
+177.60%
0.19
EBIT
-1.56
+92.30%
-20.24
+50.05%
-40.52
+47.72%
-77.51
Total Unusual Items
23.80
+878.25%
-3.06
+83.69%
-18.74
+58.37%
-45.02
Total Unusual Items Excluding Goodwill
23.80
+878.25%
-3.06
+83.69%
-18.74
+58.37%
-45.02
Special Income Charges
13.32
+535.48%
-3.06
+84.27%
-19.44
+56.81%
-45.02
Other Special Charges
-14.44
—
—
—
Impairment Of Capital Assets
1.12
-63.37%
3.06
-84.27%
19.44
-56.81%
45.02
Net Income
-1.79
+91.19%
-20.29
+48.25%
-39.21
+42.03%
-67.64
Pretax Income
-1.79
+91.16%
-20.29
+49.99%
-40.58
+47.73%
-77.62
Net Non Operating Interest Income Expense
-0.17
-160.00%
0.28
+391.07%
0.06
+343.48%
-0.02
Interest Expense Non Operating
0.23
+370.00%
0.05
-5.66%
0.05
-53.51%
0.11
Net Interest Income
-0.17
-160.00%
0.28
+391.07%
0.06
+343.48%
-0.02
Interest Expense
0.23
+370.00%
0.05
-5.66%
0.05
-53.51%
0.11
Interest Income Non Operating
0.07
-78.46%
0.33
+198.17%
0.11
+19.78%
0.09
Interest Income
0.07
-78.46%
0.33
+198.17%
0.11
+19.78%
0.09
Other Income Expense
23.39
+872.75%
-3.03
+83.85%
-18.74
+58.66%
-45.34
Other Non Operating Income Expenses
-0.41
-1416.13%
0.03
+1450.00%
0.00
+100.63%
-0.32
Gain On Sale Of Security
10.48
—
0.70
—
Tax Provision
-0.01
0.00
+100.00%
-1.37
+86.31%
-9.99
Tax Rate For Calcs
0.00
0.00
-100.00%
0.00
-73.81%
0.00
Tax Effect Of Unusual Items
0.08
0.00
+100.00%
-0.63
+89.10%
-5.79
Net Income Including Noncontrolling Interests
-1.79
+91.19%
-20.29
+48.25%
-39.21
+42.03%
-67.64
Net Income From Continuing Operation Net Minority Interest
-1.79
+91.19%
-20.29
+48.25%
-39.21
+42.03%
-67.64
Net Income From Continuing And Discontinued Operation
-1.79
+91.19%
-20.29
+48.25%
-39.21
+42.03%
-67.64
Net Income Continuous Operations
-1.79
+91.19%
-20.29
+48.25%
-39.21
+42.03%
-67.64
Normalized Income
-25.51
-48.01%
-17.23
+18.31%
-21.10
+25.74%
-28.41
Net Income Common Stockholders
-5.49
+72.96%
-20.29
+48.25%
-39.21
+42.03%
-67.64
Diluted EPS
-104.35
+97.79%
-4,718.84
+91.57%
-56,007.00
+48.00%
-107,700.64
Basic EPS
-104.35
+97.79%
-4,718.84
+89.67%
-45,696.97
+57.57%
-107,700.64
Basic Average Shares
0.05
+1122.86%
0.00
+401.17%
0.00
+36.62%
0.00
Diluted Average Shares
0.05
+1122.86%
0.00
+401.17%
0.00
+36.62%
0.00
Diluted NI Availto Com Stockholders
-5.49
+72.96%
-20.29
+48.25%
-39.21
+42.03%
-67.64
Preferred Stock Dividends
3.70
—
—
—
Line Item Trend 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total Assets
27.88
-13.98%
32.41
-14.62%
37.95
-49.25%
74.79
Current Assets
2.57
-52.15%
5.38
-27.08%
7.38
-68.60%
23.49
Cash Cash Equivalents And Short Term Investments
1.78
-58.81%
4.32
-30.02%
6.17
-72.38%
22.35
Cash And Cash Equivalents
1.78
-58.81%
4.32
-30.02%
6.17
-72.38%
22.35
Prepaid Assets
—
—
—
1.14
Other Current Assets
0.80
-25.00%
1.06
-12.03%
1.21
+5.42%
1.14
Total Non Current Assets
25.30
-6.39%
27.03
-11.61%
30.58
-40.39%
51.30
Net PPE
1.16
-28.58%
1.63
-23.07%
2.12
-37.65%
3.39
Gross PPE
4.99
-7.10%
5.37
-7.02%
5.77
-42.97%
10.12
Accumulated Depreciation
-3.83
-2.25%
-3.74
-2.27%
-3.66
+45.65%
-6.73
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
1.27
+0.95%
1.26
-0.87%
1.27
-75.04%
5.09
Other Properties
1.05
-27.22%
1.44
-22.07%
1.85
-22.18%
2.38
Leases
2.66
+0.00%
2.66
+0.57%
2.65
+0.00%
2.65
Goodwill And Other Intangible Assets
24.13
-4.44%
25.25
-10.80%
28.31
-40.72%
47.75
Goodwill
—
0.00
-100.00%
3.06
-80.50%
15.68
Other Intangible Assets
24.13
-4.44%
25.25
+0.00%
25.25
-21.27%
32.07
Other Non Current Assets
0.01
-94.00%
0.15
-2.60%
0.15
+0.00%
0.15
Total Liabilities Net Minority Interest
17.88
-38.38%
29.02
+3.84%
27.94
-15.09%
32.91
Current Liabilities
5.72
+43.07%
4.00
+62.64%
2.46
-50.09%
4.92
Payables And Accrued Expenses
3.58
+47.71%
2.43
+34.76%
1.80
-56.08%
4.10
Payables
2.14
+164.52%
0.81
+224.90%
0.25
-64.07%
0.69
Accounts Payable
1.88
+132.26%
0.81
+224.90%
0.25
-64.07%
0.69
Current Accrued Expenses
1.45
-10.69%
1.62
+4.25%
1.55
-54.46%
3.41
Total Tax Payable
0.26
0.00
—
—
Current Debt And Capital Lease Obligation
1.17
+74.74%
0.67
+1.98%
0.66
-20.19%
0.82
Current Debt
0.66
+183.69%
0.23
-7.54%
0.25
-14.29%
0.29
Other Current Borrowings
0.33
+42.92%
0.23
-7.54%
0.25
-14.29%
0.29
Current Capital Lease Obligation
0.51
+16.51%
0.44
+7.92%
0.40
-23.48%
0.53
Other Current Liabilities
0.96
+7.00%
0.90
—
—
Total Non Current Liabilities Net Minority Interest
12.16
-51.39%
25.02
-1.83%
25.48
-8.93%
27.98
Long Term Debt And Capital Lease Obligation
0.65
-43.76%
1.16
-28.51%
1.62
-21.58%
2.07
Long Term Capital Lease Obligation
0.65
-43.76%
1.16
-28.51%
1.62
-21.58%
2.07
Non Current Deferred Liabilities
4.53
-10.48%
5.06
-0.06%
5.06
-28.86%
7.11
Non Current Deferred Taxes Liabilities
4.53
-10.48%
5.06
-0.06%
5.06
-28.86%
7.11
Other Non Current Liabilities
3.80
-79.79%
18.80
+0.00%
18.80
+0.00%
18.80
Preferred Securities Outside Stock Equity
3.18
0.00
0.00
0.00
Stockholders Equity
10.00
+194.78%
3.39
-66.13%
10.01
-76.09%
41.88
Common Stock Equity
10.00
+194.78%
3.39
-66.13%
10.01
-76.09%
41.88
Capital Stock
0.00
0.00
0.00
0.00
Common Stock
0.00
0.00
0.00
0.00
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
0.26
+3748.65%
0.01
+676.46%
0.00
+36.62%
0.00
Ordinary Shares Number
0.26
+3748.63%
0.01
+676.46%
0.00
+36.62%
0.00
Treasury Shares Number
0.00
0.00
0.00
0.00
Additional Paid In Capital
859.66
+0.99%
851.27
+1.63%
837.60
+0.88%
830.26
Retained Earnings
-846.61
-0.21%
-844.82
-2.46%
-824.53
-4.99%
-785.32
Treasury Stock
3.05
+0.00%
3.05
+0.00%
3.05
+0.00%
3.05
Total Equity Gross Minority Interest
10.00
+194.78%
3.39
-66.13%
10.01
-76.09%
41.88
Total Capitalization
10.00
+194.78%
3.39
-66.13%
10.01
-76.09%
41.88
Working Capital
-3.14
-327.26%
1.38
-71.89%
4.92
-73.50%
18.57
Invested Capital
10.66
+194.07%
3.62
-64.69%
10.26
-75.66%
42.17
Total Debt
1.82
-0.44%
1.83
-19.74%
2.28
-21.19%
2.89
Capital Lease Obligations
1.16
-27.30%
1.60
-21.25%
2.03
-21.97%
2.60
Net Tangible Assets
-14.13
+35.34%
-21.86
-19.47%
-18.30
-211.63%
-5.87
Tangible Book Value
-14.13
+35.34%
-21.86
-19.47%
-18.30
-211.63%
-5.87
Current Notes Payable
0.33
0.00
—
—
Line Item Trend 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Operating Cash Flow
-15.40
-14.62%
-13.44
+30.92%
-19.45
+17.80%
-23.66
Cash Flow From Continuing Operating Activities
-15.40
-14.62%
-13.44
+30.92%
-19.45
+17.80%
-23.66
Net Income From Continuing Operations
-1.79
+91.19%
-20.29
+48.25%
-39.21
+42.03%
-67.64
Depreciation Amortization Depletion
0.08
+2.44%
0.08
-84.62%
0.53
+177.60%
0.19
Depreciation And Amortization
0.08
+2.44%
0.08
-84.62%
0.53
+177.60%
0.19
Other Non Cash Items
8.68
+2022.49%
0.41
-22.54%
0.53
-54.91%
1.17
Stock Based Compensation
0.46
-64.40%
1.28
-58.59%
3.09
-57.36%
7.24
Asset Impairment Charge
1.12
-63.37%
3.06
-84.27%
19.44
-56.81%
45.02
Deferred Tax
-0.21
0.00
+100.00%
-1.37
+86.31%
-9.99
Deferred Income Tax
-0.21
0.00
+100.00%
-1.37
+86.31%
-9.99
Operating Gains Losses
-25.34
-281633.33%
0.01
+101.30%
-0.69
-274.49%
0.40
Gain Loss On Investment Securities
-10.56
—
—
—
Unrealized Gain Loss On Investment Securities
0.22
0.00
—
—
Net Foreign Currency Exchange Gain Loss
-0.34
-11166.67%
-0.00
+99.58%
-0.71
-279.29%
0.40
Gain Loss On Sale Of PPE
0.00
-100.00%
0.01
-36.84%
0.02
0.00
Change In Working Capital
1.37
-32.06%
2.02
+213.56%
-1.78
-2963.79%
-0.06
Change In Prepaid Assets
1.08
+16.79%
0.92
-14.22%
1.08
-21.17%
1.36
Change In Payables And Accrued Expense
1.27
+102.88%
0.63
+127.43%
-2.28
-160.80%
-0.88
Change In Accrued Expense
0.20
+203.03%
0.07
+103.59%
-1.84
-351.60%
-0.41
Change In Payable
1.07
+91.07%
0.56
+226.13%
-0.44
+5.13%
-0.47
Change In Account Payable
1.07
+91.07%
0.56
+226.13%
-0.44
+5.13%
-0.47
Change In Other Current Liabilities
-0.98
-308.32%
0.47
+182.14%
-0.57
-4.20%
-0.55
Investing Cash Flow
-0.01
+20.00%
-0.01
-107.61%
0.20
+170.61%
-0.28
Cash Flow From Continuing Investing Activities
-0.01
+20.00%
-0.01
-107.61%
0.20
+170.61%
-0.28
Net PPE Purchase And Sale
-0.01
+20.00%
-0.01
-107.61%
0.20
+170.61%
-0.28
Purchase Of PPE
-0.01
+20.00%
-0.01
-15.38%
-0.01
+95.34%
-0.28
Sale Of PPE
—
0.00
-100.00%
0.21
0.00
Capital Expenditure
-0.01
+20.00%
-0.01
-15.38%
-0.01
+95.34%
-0.28
Financing Cash Flow
12.73
+9.81%
11.60
+276.58%
3.08
-89.51%
29.36
Cash Flow From Continuing Financing Activities
12.73
+9.81%
11.60
+276.58%
3.08
-89.51%
29.36
Net Issuance Payments Of Debt
1.26
+257.72%
-0.80
+32.11%
-1.17
+69.68%
-3.87
Issuance Of Debt
1.86
0.00
—
0.00
Repayment Of Debt
-0.60
+24.09%
-0.80
+32.11%
-1.17
+69.68%
-3.87
Long Term Debt Issuance
1.86
0.00
—
0.00
Long Term Debt Payments
-0.15
0.00
+100.00%
-1.17
+69.68%
-3.87
Net Long Term Debt Issuance
1.71
0.00
+100.00%
-1.17
+69.68%
-3.87
Short Term Debt Payments
-0.46
+42.91%
-0.80
+32.11%
-1.17
—
Net Short Term Debt Issuance
-0.46
+42.91%
-0.80
+32.11%
-1.17
—
Net Common Stock Issuance
5.49
-52.50%
11.55
+171.55%
4.25
-86.81%
32.23
Cash Dividends Paid
-0.66
0.00
—
—
Repurchase Of Capital Stock
-1.88
0.00
—
—
Proceeds From Stock Option Exercised
0.00
-100.00%
0.84
0.00
0.00
Net Other Financing Charges
8.52
—
—
1.00
Changes In Cash
-2.68
-44.37%
-1.86
+88.52%
-16.18
-398.56%
5.42
Beginning Cash Position
4.47
-29.36%
6.33
-71.89%
22.50
+31.71%
17.08
End Cash Position
1.79
-59.99%
4.47
-29.36%
6.33
-71.89%
22.50
Free Cash Flow
-15.41
-14.59%
-13.45
+30.89%
-19.46
+18.70%
-23.94
Common Stock Issuance
5.49
-52.50%
11.55
+171.55%
4.25
-86.81%
32.23
Issuance Of Capital Stock
5.49
-52.50%
11.55
+171.55%
4.25
-86.81%
32.23
Net Preferred Stock Issuance
-1.88
0.00
—
—
Preferred Stock Dividend Paid
-0.66
0.00
—
—
Preferred Stock Payments
-1.88
0.00
—
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category